Attgeno AB today announces positive data from the company’s Phase IIa study, evaluating the effects…
Continue Reading-
Oncoinvent Receives FDA Fast Track Designation for Radspherin®
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian…
Continue Reading -
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease Bagsværd, Denmark, and…
Continue Reading -
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa...
Continue Reading -
Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial
Alex Therapeutics Reports Positive Results...
Continue Reading -
Hadean Ventures announces oversubscribed final close of Hadean Capital II
Hadean Ventures announces oversubscribed final close of Hadean Capital II
Continue Reading -
Ribbon Biolabs appoints Jodi Barrientos Chief Executive Officer
Ribbon Biolabs appoints Jodi Barrientos Chief Executive Officer; Founder Harold De Vladar named an advisor…
Continue Reading -
Complement Therapeutics Enrols First US Participant
Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with…
Continue Reading -
Abliva Achieves Important Milestone in the Ongoing FALCON Study
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare…
Continue Reading -
Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation
Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation Abliva AB (Nasdaq Stockholm: ABLI) a…
Continue Reading